Having demonstrated the efficient CFL1 silencing by NPs(siCFL1/Sor) to enhance sorafenib sensitivity in vitro, we next evaluated whether these NPs could use this ability to inhibit HCC tumor growth. Here, CFL1 is linked to neoplasm.